PTAB/USPTO Update - April 2021

PTAB/USPTO Update - April 2021

Client Alert

Authors

 USPTO News

  • There is no USPTO news.

Notices, Guidance and Requests

Final Rules

  • There are no new final rules.

Interim Rules

  • There are no new interim rules.

Proposed Rules

  • There are no new proposed rules.

PTAB Decisions

  • New Precedential PTAB Decisions
  • There are no new precedential PTAB decisions.
  • New Informative PTAB Decisions
  • There are no new informative PTAB decisions.

New Requests for POP Review

  • Philip Morris Products v. RAI Strategic Holdings (IPR2020-01097) [Notification of Receipt of POP Request issued March 24, 2021] Petitioner requests rehearing of Institution Decision, presenting the questions of (1) whether the Fintiv analysis “should apply to IPR proceedings involving parallel ITC investigations,” (2) “whether a parallel ITC case precludes institution of an IPR,” and (3) “If a parallel ITC does not rule out institution, whether ITC respondents in the typical circumstances are required to drop all grounds that were raised, or reasonably could have been raised, in the IPR (‘IPR-eligible defenses’) from the ITC proceeding as a necessary, but not sufficient, condition to obtain institution, and whether they are required to do so unconditionally or if a Sotera-style stipulation will suffice.”
  • Nintendo Co., Ltd. et al v. Gamevice, Inc. (IPR2020-01197) [Notification of Receipt of POP Request issued March 24, 2021] Petitioner requests rehearing of Institution Decision, presenting the question of whether the Board should “(1) deny institution in view of a parallel ITC investigation and (2) apply the Fintiv factors even though they do not account for the unique aspects of an ITC investigation.”
  • SK Innovation Co., Ltd. et al v. LG Chem, Ltd. et al (IPR2020-01239 and IPR2020-01240) [Notification of Receipt of POP Request issued March 24, 2021] Petitioner requests rehearing of Institution Decisions, presenting the question of whether the Fintiv analysis “should be applied with equal force to parallel ITC proceedings without accounting for the significantly different legal impact of an Article III court and the ITC, an agency that lacks the statutory authority of a district court to invalidate a patent and whose jurisdiction and expertise in patent matters is clearly not entitled to the same deference by the Board.”
  • Regeneron Pharmaceuticals, Inc. v. Novartis Pharmaceuticals Corporation et al (IPR2020-01317) [Notification of Receipt of POP Request issued March 24, 2021] Petitioner requests rehearing of Institution Decisions, presenting the question of whether the Fintiv analysis “should ipso facto be followed to discretionarily deny institution of IPRs under 35 U.S.C. § 314(a) when there are parallel proceedings before the United States International Trade Commission (‘ITC’).”
  • 10X Genomics, Inc. v. United Kingdom Research and Innovation et al (IPR2020-01180 and IPR2020-01181) [Notification of Receipt of POP Request issued March 24, 2021] Petitioner requests rehearing of Institution Decisions, presenting the question of (1) whether the Fintiv analysis “should be clarified, modified, or abandoned,” (2) whether “stipulations requiring petitioners to agree not to raise any ground that was or could reasonably have been raised under §§ 102 or 103 on the basis of prior art patents or printed publications in district court [should] be generally available to overcome any issues related to the timing of future district court proceedings,” whether “they [should] be requested by the Board,” and when “they [can] be submitted,” and (3) whether “district courts’ schedules, including particularly dates other than dates set for the actual start of trial, [should] be excluded from the Fintiv analysis when issuing a discretionary denial of an inter partes review petition.”
  • Mitek Systems, Inc. v. United Services Automobile Association (IPR2020-01101) [Notification of Receipt of POP Request issued March 24, 2021] Petitioner requests rehearing of Institution Decisions, arguing that “the Board’s determination misapprehended the applicable standard under General Plastic and Valve, and overlooked key record evidence establishing that Mitek’s Petition is not an unfair follow-on petition.”
 

Authors

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.